A randomized, double-blind, multi-centered, placebo-controlled trial to evaluate efficacy of shexiang tongxin dropping pills in patients with coronary slow flow phenomenon

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16008950

Enrollment

Unknown

Registered

2016-08-01

Start date

2016-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart diseases

Interventions

test group:Take 4 Shexiang Tongxin dropping pills sublingually after coronary artery angiography (CAG), repeat CAG 5 minutes after the pills melt. Then take 2 pills each time, 3 times a day, for 28 da

control group:Take 4 placebo pills sublingually after coronary artery angiography (CAG), repeat CAG 5 minutes after the pills melt. Then take 2 pills each time ,3 times a day, for 28 days.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) aged 18-75 years; (2) with angina or angina like symptoms, to be diagnosed as coronary heart disease and meeting the indication of coronary angiography; (3) diagnosed coronary slow flow in at least one of the main coronary arteries by coronary angiography.

Exclusion criteria

Exclusion criteria: (1) Poorly controlled of hypertension (SBP = 160mmHg or DBP = 100mmHg) or low blood pressure (SBP 450ms) or accompanied with the diseases of torsades de points (TDP) history, such as heart failure, low blood potassium or family history of long QT syndrome , or co-use drugs that could extend QT/QTc interval; (8) Severe infection; (9) Moderate to severe anemia (HGB1.5 ULN) and psychosis; (11) Women who are pregnant or lactating; (12) Surgery and bleeding tendency in the recent 4 weeks; (13) Participating in other clinical trials in the past 1 month; (14) Allergic to known components of this drug; (15) Non-cardiovascular disease has been diagnosed, and the prognosis of the disease is poor (such as metastatic cancer) or increased risk of adverse drug reactions in the study; (16) According to the researcher's judgment, the possibility of entering the group is very little(such as the weak, etc.).Expected to survive for less than 1 years; (17) Other situations not suitable for inclusion judged by the researchers.

Design outcomes

Primary

Measure	Time frame
Corrected TIMI frame count (CTFC);	—

Secondary

Measure	Time frame
ECG;seattle angina questionnaire;major adverse cardiac events(MACE);	—

Countries

China

Contacts

Public ContactLiang Chun

Shanghai Changzheng Hospital

chunliangliang@126.com+86021-81885291

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026